Inhibikase Halts Parkinson's Drug Development to Focus on PAH

Inhibikase Therapeutics, Inc. (IKT), a biopharmaceutical company with a market capitalization of $189.48 million, has announced the halting of further development of its Parkinson's disease drug, risvodetinib, following the results of a Phase 2 clinical trial. According to InvestingPro data, the company has struggled with profitability, reporting negative EBITDA of $20.04 million in the last twelve months. The trial, which enrolled 126 participants with untreated Parkinson's disease, met its primary endpoint of safety and tolerability. However, it did not show improvement in the top hierarchical efficacy measure against placebo.